Immune checkpoint therapy that targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) significantly increased the survival of melanoma patients. This evidence concerns the gene PDCD1 and melanoma.